SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Efficacy

SOLIRIS is here... the first in-class complement inhibitor indicated for the treatment of patients with PNH to reduce hemolysis.

SOLIRIS is the first and only therapy specifically indicated to reduce hemolysis in patients with PNH

Clinical trials in PNH demonstrate that SOLIRIS® (eculizumab) is effective in treating chronic hemolysis and its associated signs and symptoms.1,2

Essential information about SOLIRIS therapy can be found in the following sections:

EfficacyHemolysis
Anemia
Transfusion Requirements
Fatigue
Patient Quality of Life
Disease-related Symptoms
Thrombotic Events

Next: Impact on Hemolysis

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References:
1. SOLIRIS® prescribing information. Alexion Pharmaceuticals, Inc. 2007.
2. Data on File. Alexion Pharmaceuticals, Inc.